Equities research analysts expect Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) to post ($1.21) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Alder BioPharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($1.98) and the highest estimate coming in at ($0.83). Alder BioPharmaceuticals reported earnings per share of ($0.70) during the same quarter last year, which would suggest a negative year over year growth rate of 72.9%. The business is scheduled to announce its next earnings report on Thursday, October 26th.

According to Zacks, analysts expect that Alder BioPharmaceuticals will report full year earnings of ($5.82) per share for the current year, with EPS estimates ranging from ($7.42) to ($4.82). For the next year, analysts anticipate that the company will report earnings of ($4.01) per share, with EPS estimates ranging from ($6.85) to ($2.83). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side analysts that follow Alder BioPharmaceuticals.

Alder BioPharmaceuticals (NASDAQ:ALDR) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.67) by $0.19. The firm had revenue of $0.68 million during the quarter. The firm’s revenue for the quarter was up 518.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.79) EPS.

ALDR has been the topic of a number of research reports. Needham & Company LLC reaffirmed a “buy” rating and set a $36.00 target price on shares of Alder BioPharmaceuticals in a research note on Friday, June 9th. Leerink Swann reaffirmed an “outperform” rating and set a $32.00 target price on shares of Alder BioPharmaceuticals in a research note on Monday, June 12th. ValuEngine raised shares of Alder BioPharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, June 20th. Credit Suisse Group lowered shares of Alder BioPharmaceuticals from an “outperform” rating to a “neutral” rating and cut their target price for the company from $30.00 to $17.00 in a research note on Wednesday, June 28th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and set a $47.00 target price on shares of Alder BioPharmaceuticals in a research note on Wednesday, June 28th. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company. Alder BioPharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $30.62.

Alder BioPharmaceuticals (ALDR) traded up 2.51% during trading on Friday, reaching $10.20. 6,499,466 shares of the company traded hands. The firm’s market capitalization is $690.67 million. Alder BioPharmaceuticals has a 12-month low of $8.60 and a 12-month high of $35.62. The firm’s 50 day moving average price is $9.67 and its 200 day moving average price is $16.14.

ILLEGAL ACTIVITY NOTICE: “-$1.21 Earnings Per Share Expected for Alder BioPharmaceuticals, Inc. (ALDR) This Quarter” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/09/15/1-21-earnings-per-share-expected-for-alder-biopharmaceuticals-inc-aldr-this-quarter.html.

In other Alder BioPharmaceuticals news, Director Stephen M. Dow purchased 25,000 shares of the stock in a transaction that occurred on Tuesday, July 18th. The stock was bought at an average cost of $10.00 per share, with a total value of $250,000.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 10.60% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Legal & General Group Plc lifted its position in Alder BioPharmaceuticals by 2.6% during the 2nd quarter. Legal & General Group Plc now owns 15,496 shares of the biopharmaceutical company’s stock valued at $177,000 after acquiring an additional 400 shares during the period. The Manufacturers Life Insurance Company lifted its position in Alder BioPharmaceuticals by 1.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 37,488 shares of the biopharmaceutical company’s stock valued at $430,000 after acquiring an additional 698 shares during the period. Teachers Advisors LLC lifted its position in Alder BioPharmaceuticals by 1.5% during the 4th quarter. Teachers Advisors LLC now owns 76,809 shares of the biopharmaceutical company’s stock valued at $1,598,000 after acquiring an additional 1,171 shares during the period. Baird Financial Group Inc. lifted its position in Alder BioPharmaceuticals by 7.9% during the 1st quarter. Baird Financial Group Inc. now owns 18,441 shares of the biopharmaceutical company’s stock valued at $384,000 after acquiring an additional 1,349 shares during the period. Finally, Swiss National Bank lifted its position in Alder BioPharmaceuticals by 2.6% during the 1st quarter. Swiss National Bank now owns 66,342 shares of the biopharmaceutical company’s stock valued at $1,380,000 after acquiring an additional 1,700 shares during the period. 76.16% of the stock is owned by institutional investors.

Alder BioPharmaceuticals Company Profile

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

Get a free copy of the Zacks research report on Alder BioPharmaceuticals (ALDR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alder BioPharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.